NCCIH Natural Product Early Phase Clinical Trial Award (R33 Clinical Trial Required)
ID: 352163Type: Posted
Overview

Buyer

National Institutes of Health (HHS-NIH11)

Award Range

$0 - $1M

Eligible Applicants

Others

Funding Category

Health

Funding Instrument

Grant

Opportunity Category

Discretionary

Cost Sharing or Matching Requirement

Yes

Original Source

https://grants.gov/search-results-detail/352163

Additional Information

http://grants.nih.gov/grants/guide/pa-files/PAR-24-116.html
Timeline
    Description

    The National Institutes of Health (NIH) is offering the Natural Product Early Phase Clinical Trial Award (R33), aimed at funding early-phase clinical trials for promising natural products, including botanicals and dietary supplements. This funding opportunity encourages applications that assess target engagement and the relationship between the intervention and clinical outcomes over a maximum period of three years, with total funding not exceeding $1,050,000. The program emphasizes the importance of rigorous and reproducible trials, particularly in managing conditions such as pain and mental health disorders, while requiring a Plan for Enhancing Diverse Perspectives (PEDP) to ensure inclusivity in research. Interested applicants must submit their proposals by November 14, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.

    Point(s) of Contact
    grantsinfo@nih.gov
    Files
    Title
    Posted
    PAR-24-116-Full-Announcement.html
    PAR-24-116.html
    The National Center for Complementary and Integrative Health (NCCIH) is offering the Natural Product Early Phase Clinical Trial Award (R33), aimed at funding early-phase clinical trials for promising natural products such as botanicals and dietary supplements. This funding opportunity encourages applications focused on trials that assess target engagement and the relationship between the intervention and clinical outcomes over a maximum period of three years, with total funding not exceeding $1,050,000. Key areas of interest include the management of conditions such as pain and mental health disorders. Applicants must adhere to strict regulatory guidelines and demonstrate adequate preliminary data to support their studies. A Plan for Enhancing Diverse Perspectives (PEDP) is also mandatory, ensuring diverse stakeholder engagement and inclusivity in the research approach. The program prioritizes rigor and reproducibility in trials, and only those that do not seek to assess efficacy or treatment of cancer will be considered. The deadline for application submissions is set for November 14, 2026, with multiple review cycles planned before the award decisions.
    Similar Opportunities
    NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), invites applications for the NCCIH Natural Product Early Phase Clinical Trial Phased Innovation Award (R61/R33), aimed at supporting early-phase clinical trials of natural products such as botanicals and dietary supplements. This funding opportunity encourages research that evaluates the pharmacokinetics, safety, and efficacy of these natural products, with a focus on advancing promising interventions backed by prior scientific evidence. The program is designed to foster innovative clinical research that enhances understanding of the beneficial impacts of natural products on health conditions, while ensuring inclusivity through a Plan for Enhancing Diverse Perspectives (PEDP). Applicants may request up to $350,000 per year, with a project duration of up to six years contingent upon successful milestone completion, and the application deadline is November 13, 2026. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov.
    NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), is inviting applications for the "NCCIH Natural Product Mid Phase Clinical Trial (R01 Clinical Trial Required)" grant, aimed at advancing research on natural products such as botanicals and dietary supplements. This funding opportunity encourages mid-phase clinical trials that are hypothesis-driven, focusing on determining optimal dosing or identifying patient phenotypes for future efficacy studies, while explicitly excluding trials for cancer treatment. Eligible applicants include a diverse range of organizations, such as historically black colleges, tribal colleges, and community-based organizations, with a funding ceiling of $350,000 and a submission deadline of November 13, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at http://grants.nih.gov/grants/guide/pa-files/PAR-24-115.html.
    Clinical Coordinating Center for NCCIH Multi-Site Investigator-Initiated Clinical Trials of Natural Products (Collaborative UG3/UH3 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the establishment of a Clinical Coordinating Center (CCC) to support multi-site investigator-initiated clinical trials focused on natural products, such as botanicals and dietary supplements. Applicants are required to submit a comprehensive plan detailing project management, participant recruitment, and clinical trial execution, while also ensuring alignment with NIH standards. This initiative emphasizes the importance of evidence-based research in natural products and mandates the submission of a corresponding Data Coordinating Center (DCC) proposal to oversee data management and analysis. Interested applicants should note that the application deadline is July 15, 2026, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries. For additional details, applicants can refer to the full announcement available at https://grants.nih.gov/grants/guide/pa-files/PAR-24-123.html.
    Discovery and Development of Natural Products for Cancer Interception and Prevention (UG3/UH3 Clinical Trial Not Allowed)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the Discovery and Development of Natural Products for Cancer Interception and Prevention, specifically through a cooperative agreement mechanism. This initiative aims to support the discovery and development of novel, safe, and effective natural products that target cancer prevention, structured in two phases: the UG3 phase for initial screenings and assay development lasting up to three years, followed by the UH3 phase for full-scale evaluations lasting up to two years. The program emphasizes the importance of high-throughput screening strategies and collaboration with existing NCI natural product libraries, with a total funding allocation of $4.5 million for approximately 12 awards. Interested applicants must submit their proposals by June 13, 2025, and can direct inquiries to grantsinfo@nih.gov for further information.
    NHLBI Early Phase Clinical Trials for Therapeutics and/or Diagnostics for HLBS Disorders (R33 CT Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for the NHLBI Early Phase Clinical Trials (R33), aimed at supporting investigator-initiated Phase I clinical trials for therapeutic and diagnostic interventions targeting heart, lung, blood, and sleep (HLBS) disorders. Applicants are required to be prepared to initiate their clinical trials within the first quarter of the project period and must demonstrate readiness in obtaining necessary regulatory approvals, including FDA and IRB, prior to the award. This funding is crucial for addressing unmet medical needs through innovative research, with a maximum budget of $1.515 million per year and a project duration of up to three years, contingent upon achieving specific milestones. Interested applicants should note the application deadline of June 4, 2024, and can direct inquiries to NIH Grants Information at grantsinfo@nih.gov for further details.
    Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R33 Clinical Trial Optional)" aimed at advancing innovative research into precision probiotic interventions. This initiative seeks applications that will investigate person-specific factors influencing probiotic responses, such as microbiome composition, age, sex, genetic background, and lifestyle, to identify subgroups that may benefit from tailored probiotic treatments. The funding is crucial for addressing variability in human responses to probiotics and aims to enhance health outcomes through targeted interventions. Applicants can request up to $350,000 per year for a maximum of four years, with the application deadline set for June 2, 2027. For further inquiries, interested parties can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-239.html.
    NINDS Exploratory Clinical Trials for Small Business (R43/R44 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity for small business concerns (SBCs) through the NINDS Exploratory Clinical Trials program (R43/R44), aimed at supporting investigator-initiated exploratory clinical trials related to neurological disorders. This program invites applications for studies that evaluate drugs, biologics, devices, or therapies, generating preliminary data to inform future clinical development, with a focus on enhancing diverse perspectives within research teams. Eligible U.S.-based SBCs can apply for funding caps of up to $295,924 for Phase I and $1,972,828 for Phase II, with applications due by September 5, 2026. For further inquiries, applicants can contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-23-311.html.
    Feasibility Clinical Trials of Mind and Body Interventions for NCCIH High Priority Research Topics (R34 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH), through the National Center for Complementary and Integrative Health (NCCIH), is offering a funding opportunity for feasibility clinical trials focused on mind and body interventions addressing high-priority research topics. The objective is to support R34 planning grants that gather essential data necessary for the design and planning of future full-scale efficacy studies, specifically examining aspects such as intervention acceptability, recruitment strategies, and data collection procedures. This initiative is crucial for advancing research in nonpharmacological approaches to symptom management, particularly relevant in the context of increasing healthcare demands. Interested applicants can apply for grants of up to $450,000 over three years, with a submission deadline of November 13, 2026. For further inquiries, applicants may contact NIH Grants Information at grantsinfo@nih.gov or visit the additional information link at https://grants.nih.gov/grants/guide/pa-files/PAR-24-084.html.
    Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is inviting applications for the funding opportunity titled "Enhancing Mechanistic Research on Precision Probiotic Therapies (R61/R33 Clinical Trial Optional)." This initiative aims to support innovative mechanistic research that addresses the variability in individual responses to probiotics, with the goal of developing effective interventions tailored to person-specific biological features. The funding mechanism employs a biphasic approach, where the R61 phase focuses on identifying host biological patterns correlated with probiotic effects through observational studies, and the R33 phase rigorously tests causality in animal or human studies, with a total budget not exceeding $350,000 per year for both phases. Interested applicants must submit their proposals by June 2, 2027, and can reach out to NIH Grants Information at grantsinfo@nih.gov for further inquiries.
    NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)
    Active
    National Institutes of Health
    The National Institutes of Health (NIH) is offering a funding opportunity titled "NINDS Exploratory Clinical Trials for Small Business (R41/R42 Clinical Trial Required)" aimed at supporting Small Business Concerns (SBCs) in conducting investigator-initiated exploratory clinical trials related to neurological disorders. This initiative encourages applications for Phase I and II studies focusing on drugs, biologics, devices, and therapies that align with the mission of the National Institute of Neurological Disorders and Stroke (NINDS), emphasizing the inclusion of a Plan for Enhancing Diverse Perspectives (PEDP) to foster innovation. The maximum funding amounts are $295,924 for Phase I and $1,972,828 for Phase II projects, with applications required to demonstrate readiness for eventual FDA regulatory approval. Interested applicants can begin submitting proposals on December 5, 2023, with the application deadline set for September 5, 2026; for further inquiries, contact NIH Grants Information at grantsinfo@nih.gov.